RxDoctor Payments Data

Mark Austin, MD

Ophthalmology · Appleton, WINPI 1487697959

Payments from drug & device makers

$1,263in general payments, 2019–2025

Across 56 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$374
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$338
  • Novartis$115
  • Oyster Point Pharma, Inc.$103
  • Alcon$64
  • Apellis Pharmaceuticals, Inc.$47
  • plus $222 from 9 others

What the payments were for

  • Food & beverage$1,20896%
  • Education$554%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,263 in reported general payments places this provider in the 70th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$61,435
Medicare patients
411
Services billed
734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine43$57,094
XiidraLifitegrast16$19,729
LumiganBimatoprost38$18,645
Timolol Maleate450$17,471
Cyclosporine25$14,494
Latanoprost963$13,555
Travoprost29$6,943
Loteprednol Etabonate30$5,674
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol36$4,791
Prednisolone Acetate93$3,977
Tobramycin-DexamethasoneTobramycin/Dexamethasone70$2,959
Brinzolamide17$2,606
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat56$1,418
Dorzolamide Hcl28$760
Brimonidine Tartrate30$536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$374$75,73981 claims
Bausch & Lomb Americas Inc.Xiidra$41$19,72916 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$338$5,67430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in Appleton

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →